Dr Reddy’s plunges 5% – Should investors Buy or Sell now? Analysts weigh in

Dr Reddy’s share price dropped due to a Notice of Non-Compliance from Canada’s Pharmaceutical Drugs Directorate. Nomura predicts no approval before 2026 patent expiry, limiting potential growth. Despite reducing target price, the brokerage maintains a ‘Buy’ rating due to attractive valuation compared to peers. The stock has declined in recent trading sessions and the past […]